Gastroesophageal Reflux Disease and Barrett’s Esophagus

References

• 1 Wu C J, Chan F KI, Ching J YI, et al. Heartburn and acid regurgitation are unreliable diagnostic indicators of gastroesophageal reflux disease (GERD) in populations with high prevalence of H. pylori infection [abstract].  Gastroenterology. 2001;  120 A 729
• 2 Johanson J, Hwang C, Roach A. Prevalence of erosive esophagitis (EE) in patients with gastroesophageal reflux disease (GERD) [abstract].  Gastroenterology. 2001;  120 A 233
• 3 Fujiwara Y, Higuchi K, Tominaga K, et al. Association between gastroesophageal flap valve, reflux esophagitis, Barrett’s epithelium, and atrophic gastritis assessed by endoscopy in Japanese patients [abstract].  Gastrointest Endosc. 2001;  53 AB 142
• 4 Winters G R, Wong R K, Maydonovitch C L. Is Schatzki’s ring protective against acid reflux? [abstract].  Gastrointest Endosc. 2001;  53 AB 149
• 5 Inadomi J M, Lieberman D, Lagergren J, et al. Cost-effectiveness of once in a lifetime screening unsedated endoscopy in 50-year-old males with uncomplicated GERD [abstract].  Gastroenterology. 2001;  120 A 414
• 6 Tam W CE, Dent J, Conroy-Hiller T A, et al. Proposed new endoscopic criteria for minimal change reflux esophagitis based on magnification endoscopy [abstract].  Gastrointest Endosc. 2001;  53 AB 119
• 7 Park P O, Kjellin T H. Results of endoscopic gastroplasty for gastroesophageal reflux disease [abstract].  Gastrointest Endosc. 2001;  53 AB 115
• 8 Raijman I, Ben-Menachem T, Reddy D, et al. Symptomatic response to endoluminal gastroplication (ELGP) in patients with gastroesophageal reflux disease (GERD): a multicenter experience [abstract].  Gastrointest Endosc. 2001;  53 A 74
• 9 Mahmood Z, McMahon B P, Khosa F, et al. Transesophageal endoscopic gastroplication (TEG) treatment for gastroesophageal reflux disease (GERD) [abstract].  Gastrointest Endosc. 2001;  53 AB 141
• 10 Haber G B, Marcon N E, Kortan P, et al. A year follow-up of 25 patients undergoing endoluminal gastric plication (ELGP) for gastroesophageal reflux disease (GERD) [abstract].  Gastrointest Endosc. 2001;  53 AB 116
• 11 Pohl H, Wood K M, Rothstein R I. Endoscopic therapy for gastroesophageal reflux disease (GERD): early experience with the Bard endoscopic suturing system (BESS) and Stretta in one institution [abstract].  Gastrointest Endosc. 2001;  53 AB 126
• 12 Tam W CE, Schoeman M N, Zhang Q, et al. Delivery of radiofrequency energy (RFe) to the lower esophageal sphincter (LES) and gastric cardia inhibits transient LES relaxations and gastroesophageal reflux in patients with reflux disease [abstract].  Gastroenterology. 2001;  120 A 16
• 13 Lehman G A, Devière J, Haber G, et al. Lower esophageal sphincter (LES) augmentation therapy for GERD with Eneterix, a biocompatible inert polymer: initial multicenter human trial results [abstract].  Gastrointest Endosc. 2001;  53 A 123
• 14 Devière J, Silverman D, Pastorelli A, et al. Endoscopic implantation of a biopolymer in the lower esophageal sphincter for gastroesophageal reflux: a pilot study [abstract].  Gastrointest Endosc. 2001;  53 AB 74
• 15 Benipal P S, Fass R, Stanley T S, et al. Prevalence of short-segment Barrett’s esophagus (SSBE): have we reached a plateau? [abstract].  Gastrointest Endosc. 2001;  53 AB 160
• 16 Borovicka J, Hurschler D, Neuweiler J, et al. Increased detection rates of Barrett’s esophagus without rise in incidence of esophageal adenocarcinoma: a ten-year survey in eastern Switzerland [abstract].  Gastroenterology. 2001;  120 A 416
• 17 Covas A, Franchimont D, Le M oine. Early development of Barrett’s esophagus after subtotal esophagectomy [abstract].  Gastroenterology. 2001;  120 A 413
• 18 Lee T J, Brock W E, Goddard K, et al. Familial aggregation of Barrett’s esophagus and esophageal adenocarcinoma [abstract].  Gastrointest Endosc. 2001;  53 AB 143
• 19 Fang J C, Berenson M, Samowitz W, et al. Familial Barrett’s esophagus: is the key erosive esophagitis in young adults? [abstract].  Gastroenterology. 2001;  120 A 415-A 416
• 20 Voderholzer W A, Loening-Baucke V, Neudecker J, et al. Biliary and acid reflux in Barrett’s esophagus: which one plays the key role? [abstract].  Gastroenterology. 2001;  120 A 418
• 21 Kearney D J, Crump C, Maynard C, et al. A case-control study of endoscopy and mortality from adenocarcinoma of the esophagus of gastric cardia (AEGC) for persons with gastroesophageal reflux disease (GERD) [abstract].  Gastroenterology. 2001;  120 A 414
• 22 Avidan B, Sonnenberg A, Schnell T G, et al. Risk factors for esophageal adenocarcinoma: a case-control study [abstract].  Gastroenterology. 2001;  120 A 442
• 23 Al-Mutawa T S, Malagon I, Gareway H, et al. Correlation between the length of Barrett’s esophagus and the size of hiatal hernia [abstract].  Gastrointest Endosc. 2001;  53 AB 154
• 24 Sampliner R E, Eisen G M, DeGarmo P. Ethnicity and gender of patients with suspected Barrett’s esophagus in a large endoscopy cohort (CORI) [abstract].  Gastrointest Endosc. 2001;  53 AB 151
• 25 Sampliner R E, Eisen G M, DeGarmo P. Demographic and clinical risk factors differ between long- and short-segment suspected Barrett’s esophagus [abstract].  Gastrointest Endosc. 2001;  53 AB 155
• 26 Goldblum J R, Richter J E, Vaezi M F, et al. H. pylori (HP), not GERD, is the major cause of inflammation and intestinal metaplasia (IM) of the native gastric cardia [abstract].  Gastroenterology. 2001;  120 A 412
• 27 Lung E, Levin T R, Habel L, et al. Prevalence of gastric metaplasia without intestinal metaplasia among patients with adenocarcinoma of the esophagus [abstract].  Gastrointest Endosc. 2001;  53 AB 146
• 28 Souto E O, Cameron A J, Smyrk T C. Small adenocarcinomas of the cardia: association with intestinal metaplasia and dysplasia [abstract].  Gastroenterology. 2001;  120 A 442-A 443
• 29 Falk G W, Ours T M, Easley K, et al. Could a simple questionnaire enhance endoscopic screening for Barrett’s esophagus? [abstract].  Gastroenterology. 2001;  120 A 414
• 30 Gerson L B, Shetler K, Triadafilopoulos G. Screening for Barrett’s esophagus in asymptomatic adults undergoing routine flexible sigmoidoscopy for colorectal cancer screening [abstract].  Gastrointest Endosc. 2001;  53 AB 61
• 31 Ghorai S, Rex D, Cummings O, et al. Screening for Barrett’s (B) in colonoscopy (CS) patients with and without heartburn (HB) [abstract].  Gastrointest Endosc. 2001;  53 AB 61
• 32 Mokhashi M S, Glenn T F, Jost C, et al. A 4-minute unsedated office-based screening esophagoscopy for Barrett’s: a blinded prospective comparative study of diagnostic accuracy and tolerance of esophagoscopy with a battery-powered esophagoscope (BPE) with a sedated standard video-endoscopy (SVE) [abstract].  Gastrointest Endosc. 2001;  53 AB 62
• 33 Saeian K, Vasipoulos S, Staff D, et al. Does biopsy size of unsedated transnasal endoscopy (T-EGD) impact histologic interpretation of Barrett’s dysplasia? [abstract].  Gastrointest Endosc. 2001;  53 AB 157
• 34 Weinstein W M, Leh W W, Wiggett S D. False-positive diagnoses of Barrett’s esophagus are common. Why do they occur? [abstract].  Gastroenterology. 2001;  120 A 442
• 35 Dave U, Mahadeva U, Loh V, et al. Peri-Z-line biopsy routine upper GI endoscopy: from where and how many? [abstract].  Gastroenterology. 2001;  120 A 428
• 36 Chauhan T C, Waxman M, Ho I K. Nonulcer dyspepsia and intestinal metaplasia (IM) of the gastric cardia [abstract].  Gastrointest Endosc. 2001;  53 AB 219
• 37 Huh C, Henry M, Darwin P E. Brush cytology via unsedated esophagoscopy for the diagnosis of Barrett’s esophagus [abstract].  Gastrointest Endosc. 2001;  53 AB 158
• 38 Falk G W, Provencher K A, Gramlich T L, et al. Surveillance of Barrett’s esophagus with a modified nonendoscopic cytology device: a pilot study [abstract].  Gastrointest Endosc. 2001;  53 AB 157
• 39 Glickman J N, Ormsby A H, Gramlich T H, et al. Interinstitutional variability in the interpretation of cytokeratin 7/20 (CK 7/20) staining patterns in Barrett’s esophagus (BE) [abstract].  Gastroenterology. 2001;  120 A 415
• 40 Mullic T, Tasch J E, Ormsby A H, et al. Telomerase: a potential biomarker of adenocarcinoma in Barrett’s esophagus [abstract].  Gastroenterology. 2001;  120 A 413
• 41 Dulai G S, Ganz P, Kahn K, et al. Barrett’s screening practices of primary care providers in California [abstract].  Gastrointest Endosc. 2001;  53 AB 192
• 42 Pruthi J S, Dulai G S, Elguindy A, et al. Barrett’s esophagus: surveillance in an HMO setting [abstract].  Gastrointest Endosc. 2001;  53 AB 160
• 43 Dulai G S, Chen J, Oh D, et al. Cancer risk, EGD biopsy workload and reporting in a VA Barrett’s cohort [abstract].  Gastroenterology. 2001;  120 A 416-A 417
• 44 Quinonez N F, Rodriguez E D. Length of Barrett’s esophagus and risk of dysplasia in Hispanics [abstract].  Gastroenterology. 2001;  120 A 418
• 45 Ronkrainen J, Aro P, Storskrubb T, et al. How persistent is short-segment Barrett’s esophagus in the general population? A report from the Kalixanda study [abstract].  Gastroenterology. 2001;  120 A 232-A 233
• 46 Sharma P, Reker D, Falk G W, et al. Progression of Barrett’s esophagus to high-grade dysplasia and cancer: preliminary results of the BEST (Barrett’s Esophagus Study Trial) [abstract].  Gastroenterology. 2001;  120 A 16-A 17
• 47 Corley D A, Levin T R, Habel L, et al. Association between surveillance and survival in Barrett’s adenocarcinoma: a population-based study [abstract].  Gastroenterology. 2001;  120 A 17
• 48 Dar M, Goldblum J R, Rice T W, et al. Unifocal versus multifocal high-grade dysplasia in Barrett’s esophagus does not predict adenocarcinoma at esophagectomy [abstract].  Gastroenterology. 2001;  120 A 416
• 49 Sontag S J, Schnell T G, Chejfec G, et al. Dysplasia: negative for, indefinite for, and low grade have no prognosis value for Barrett’s cancer [abstract].  Gastroenterology. 2001;  120 A 403
• 50 Murray L M, Watson R GP, Johnston B T, et al. Low risk of adenocarcinoma in Barrett’s oesophagus: results of a population-based study [abstract].  Gastroenterology. 2001;  120 A 414
• 51 Provenzale D. Immediate esophagectomy or continued surveillance for Barrett’s patients with high-grade dysplasia? A decision analysis [abstract].  Gastroenterology. 2001;  120 A 414
• 52 Vazquez-Iglesias J L, Canalejo J, Gonzalez-Conde J, et al. The usefulness of methylene blue staining for the detection of intestinal metaplasia of the gastric cardia [abstract].  Gastrointest Endosc. 2001;  53 AB 120
• 53 Sharma P, Weston A P, Sampliner R E. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett’s esophagus [abstract].  Gastrointest Endosc. 2001;  53 AB 62
• 54 Shrestha S, Xiao S Y, Reeves A L, et al. Can high resolution and high-magnification endoscopy (HRHME) accurately predict the presence of specialized intestinal metaplasia in patients with Barrett’s esophagus and serve as a surrogate optical biopsy? [abstract].  Gastrointest Endosc. 2001;  53 AB 121
• 55 DeWeerth A, Brand B, Fritscher-Ravens A, et al. High-resolution zoom endoscopy combined with vital staining for improved accurate detection of dysplasia in Barrett’s mucosa: preliminary results from an ongoing study [abstract].  Gastrointest Endosc. 2001;  53 AB 160
• 56 Canto M IF, Wu T T, Kalloo A N. High-magnification endoscopy with methylene blue chromoendoscopy for improved diagnosis of Barrett’s esophagus and dysplasia [abstract].  Gastrointest Endosc. 2001;  53 AB 159
• 57 Sueoka N, Tabuchi M, Nishigaki H, et al. Magnification endoscopy with vital dye staining for detection of a minute focus of early adenocarcinoma in Barrett’s esophagus [abstract].  Gastrointest Endosc. 2001;  53 AB 150
• 58 Ponchon T, Chavaillon A, Saurin J C, et al. Detection of high-grade dysplasia and superficial carcinoma on Barrett’s esophagus by chromoscopy and magnification [abstract].  Gastrointest Endosc. 2001;  53 AB 151
• 59 Banerjee B, Agarwal S, Chandrasekhar H R. Autofluorescence spectroscopy to differentiate high-grade dysplasia and cancer from low-grade dysplasia in Barrett’s esophagus [abstract].  Gastrointest Endosc. 2001;  53 AB 153
• 60 Haringsma J, Tytgat N J. Fluorescence imaging of high-grade dysplasia in Barrett’s esophagus [abstract].  Gastrointest Endosc. 2001;  53 AB 148
• 61 Wang K K, Buttar N S, Wong Kee Song L M, et al. The use of an optical biopsy system in Barrett’s esophagus [abstract].  Gastroenterology. 2001;  120 A 413
• 62 Zuccaro G, Gladkova N, Vargo J J, et al. Optical coherence tomography (OCT) in the diagnosis of Barrett’s esophagus (BE), high-grade dysplasia (HGD), intramucosal adenocarcinoma (IMAC) and invasive adenocarcinoma (INVAC) [abstract].  Gastrointest Endosc. 2001;  53 AB 62
• 63 Poneros J M, Tearney G J, Bouma B E, et al. Diagnosis of dysplasia in Barrett’s esophagus using optical coherence tomography [abstract].  Gastrointest Endosc. 2001;  53 AB 113
• 64 Wong K ee, Shim M G, Wilson B C, et al. In vivo endoscopic Raman spectroscopy for the differentiation of dysplasia (low-grade versus high-grade) within Barrett’s esophagus [abstract].  Gastrointest Endosc. 2001;  53 AB 109
• 65 Dulai G S, Jensen D M, Weinstein W M, et al. Screening of patients referred for a Barrett’s ablation protocol: findings and implications for patients and providers [abstract].  Gastrointest Endosc. 2001;  53 AB 158
• 66 Tsai P I, Wickramsinghe K, Bremner C G, et al. Barrett’s mucosal thickness: a consideration during ablation [abstract].  Gastroenterology. 2001;  120 A 410
• 67 Overholt B F, Panjehpour M, Haydek J M, et al. Photodynamic therapy (PDT) for Barrett’s esophagus with dysplasia: long-term results [abstract].  Gastrointest Endosc. 2001;  53 AB 73
• 68 Beejay U, Ribeiro A, Hourigan L, et al. Photodynamic therapy of high-grade dysplasia/intramucosal carcinoma in Barrett’s esophagus: 30 months’ follow-up [abstract].  Gastrointest Endosc. 2001;  53 AB 144
• 69 Kahaleh M, van Laethem J L, Nagy N, et al. Long-term follow-up and predictive factors of recurrence in Barrett’s esophagus treated by argon plasma coagulation and omeprazole [abstract].  Gastroenterology. 2001;  120 A 411-A 412
• 70 Morris C D, Byrne J P, Attwood S E. Endoscopic ablation of Barrett’s esophagus by argon beam plasma coagulation: long-term follow-up [abstract].  Gastrointest Endosc. 2001;  53 AB 145
• 71 Familiari L, Bonica M, Consolo P, et al. Endoscopic argon-plasma coagulation (APC) of Barrett’s esophagus: long-term follow-up [abstract].  Gastrointest Endosc. 2001;  53 AB 158
• 72 Fusaroli P, Togliani T, Eleonori S, et al. Endoscopic argon plasma coagulation for reversal of Barrett’s metaplasia: the shorter the better? [abstract].  Gastrointest Endosc. 2001;  53 AB 148
• 73 Pereira-Lima J C, Toneloto E B, Lopes C V, et al. High power-setting argon plasma coagulation ablates Barrett’s esophagus without leaving intestinal metaplasia underneath the new squamous epithelium [abstract].  Gastrointest Endosc. 2001;  53 AB 37
• 74 Burdick J S, Dykes C M, Lindberg G M, et al. Factors which influence the efficacy of PDT in HGD and adenocarcinoma of the esophagus [abstract].  Gastrointest Endosc. 2001;  53 AB 141
• 75 Schattner M A, da Carlsson M, Ahdoot A, et al. Risk factors for photodynamic therapy induced strictures of the esophagus [abstract].  Gastrointest Endosc. 2001;  53 AB 159
• 76 Wang K K, Lutzke L S, Buttar N S, et al. Do non-steroidal anti-inflammatory drugs (NSAIDS) influence treatment outcome in photodynamic therapy (PDT) of Barrett’s esophagus? [abstract].  Gastrointest Endosc. 2001;  53 AB 156
• 77 Krishnadath K, Wang K K, Taniguchi K, et al. Mutations in Barrett’s esophagus predict poor response to photodynamic therapy [abstract].  Gastroenterology. 2001;  120 A 413
• 78 Morris C D, Tselepis C, Harrison R, et al. Characterization of classical and desmosomal cadherins in the neo-squamous epithelium after endoscopic ablation of Barrett’s esophagus [abstract].  Gastroenterology. 2001;  120 A 416
• 79 Lenz M, Hoepfner M, Theiss A, et al. Hypericin is an encouraging new photosensitizer for photodynamic therapy of esophageal dysplasia/cancer: antiproliferative and apoptotic effects [abstract].  Gastroenterology. 2001;  120 A 443
• 80 Fass R, Garewal H S, Pulliam G, et al. Chemoreceptor sensitivity and esophageal motor function before and after reversal of Barrett’s esophagus (BE) with endoscopic multipolar electrocoagulation (MPEC) [abstract].  Gastroenterology. 2001;  120 A 415
• 81 Giovannini M, Bories E, Ries P, et al. Long-term follow-up of patients treated by endoscopic mucosal resection (EMR) guided by high-frequency EUS for superficial esophageal cancer [abstract].  Gastroenterology. 2001;  120 A 442
• 82 Ponchon T, Saurin J C. Circumferential endoscopic mucosal resection for Barrett’s esophagus: in vitro studies on pigs [abstract].  Gastrointest Endosc. 2001;  53 AB 159
• 83 Rajan E, Burgart L J, Herman L J, et al. Widespread endoscopic mucosal resection (WEMR) of the esophagus with strategies for stricture prevention [abstract].  Gastrointest Endosc. 2001;  53 AB 126
• 84 Eastone J A, Horwhat D, Haluska O, et al. Cryoablation of swine esophageal mucosa: a direct comparison to argon plasma coagulation (APC) and multipolar electrocoagulation (MPEC) [abstract].  Gastrointest Endosc. 2001;  53 AB 121